

Edgar Filing: JOHNSON & JOHNSON - Form 8-K

JOHNSON & JOHNSON  
Form 8-K  
January 18, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8K

Current Report Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12,  
2005

JOHNSON & JOHNSON

(Exact name of registrant as specified in its charter)

New Jersey	1-3215	22-1024240
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of principal executive offices) (zip code)

Registrant's telephone number including area code: (732) 524-  
0400

Check the appropriate box below if the Form 8-K filing is  
intended to  
simultaneously satisfy the filing obligation of the registrant  
under any of the following provisions:

Written communications pursuant to Rule 425 under the  
Securities Act  
(17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the  
Exchange Act  
(17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b)  
under the  
Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c)  
under the  
Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

## Edgar Filing: JOHNSON & JOHNSON - Form 8-K

On January 12, 2005, Johnson & Johnson announced that Christine A. Poon, Executive Committee Member and Worldwide Chairman, Medicines & Nutritionals, has been appointed Vice Chairman of Johnson & Johnson. In addition, the Nominating & Corporate Governance Committee of the Board of Directors has nominated Ms. Poon for election to the Board at the Annual Meeting of Shareholders in April 2005. Ms. Poon will continue to have management responsibility for all pharmaceutical, consumer pharmaceutical, and nutritional businesses and report directly to Mr. Weldon.

Ms. Poon, age 52, was appointed Worldwide Chairman, Medicines and Nutritionals, in 2003. Previously she served as Worldwide Chairman, Pharmaceuticals, a position she assumed in 2001. She joined Johnson & Johnson in November 2000 as Company Group Chairman, Pharmaceuticals, after a 15-year career with Bristol-Myers Squibb, a global pharmaceutical company, where she held numerous senior level management assignments. In her last position there she served as President of International Medicines.

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JOHNSON & JOHNSON

Date: January 18, 2005

By: /s/ Michael H. Ullmann  
Michael H. Ullmann  
Corporate Secretary